Please check your internet connection and try again.
# Urimax (Tamsulosin)
## Overview
Tamsulosin is a selective alpha-1 adrenergic receptor antagonist that primarily blocks the alpha-1A subtype found in prostate smooth muscle, bladder neck, and urethra, reducing smooth muscle tone to improve urinary flow.
## Primary Indications
* Signs and symptoms of Benign Prostatic Hyperplasia (BPH).
* Off-label: Medical Expulsive Therapy (MET) for ureteral calculi (distal stones).
## Adult Dosing
* **BPH:** 0.4 mg orally once daily, taken 30 minutes after the same meal each day.
* If no response after 2–4 weeks at 0.4 mg, dose may be increased to 0.8 mg once daily.
* **Maximum Dose:** 0.8 mg daily.
## Pediatric Dosing
**Not indicated.** Safety and efficacy have not been established in the pediatric population.
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment required.
* **Hepatic Impairment:** No dosage adjustment typically required for mild/moderate impairment. Urimax has not been studied in patients with severe hepatic impairment; use with caution.
* **CYP3A4 Inhibitors:** If initiated or discontinued in patients taking strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin), monitor closely.
## Contraindications
* Known hypersensitivity to tamsulosin or any component of the formulation.
## Adverse Effects
* **Common:** Dizziness, orthostatic hypotension, headache, abnormal ejaculation (retrograde ejaculation), rhinitis, and asthenia.
* **Serious:** Severe hypotension/syncope (especially upon initiation), Floppy Iris Syndrome (IFIS) during cataract surgery.
## Key Drug Interactions
* **PDE-5 Inhibitors (e.g., sildenafil, tadalafil):** Concurrent use may lead to additive hypotensive effects. Use with caution; initiate tamsulosin at the lowest dose.
* **Strong CYP3A4 Inhibitors:** May significantly increase plasma concentrations of tamsulosin.
* **Antihypertensives:** Potential for additive blood pressure lowering effects.
## Monitoring
* Monitor blood pressure periodically, especially following the initial dose or dose increases (risk of orthostatic hypotension).
* Assess for improvement in BPH symptom scores (e.g., IPSS).
* Screen for cataract/glaucoma history prior to initiation; warn ophthalmologist of tamsulosin use before cataract surgery to mitigate risk of Intraoperative Floppy Iris Syndrome.
## Clinical Pearls
* **Administration:** Must be taken 30 minutes after the same meal each day to ensure consistent bioavailability. Do not crush, chew, or open capsules.
* **First-Dose Phenomenon:** Dizziness or syncope can occur after the first dose. Advise patients to rise slowly from a sitting or lying position.
* **Efficacy:** While prostate volume may take time to decrease with other therapies (like 5-alpha-reductase inhibitors), tamsulosin provides symptomatic relief relatively quickly.
***
*Disclaimer: This information is for educational purposes only. Clinical protocols may vary by institution. Always verify current prescribing information, contraindications, and drug interactions via a reliable clinical database (e.g., Lexicomp, UpToDate) before prescribing or administering medication.*
